These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 23266703)

  • 1. Custirsen (OGX-011): clusterin inhibitor in metastatic prostate cancer.
    Al-Asaaed S; Winquist E
    Curr Oncol Rep; 2013 Apr; 15(2):113-8. PubMed ID: 23266703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer.
    Zielinski R; Chi KN
    Future Oncol; 2012 Oct; 8(10):1239-51. PubMed ID: 23130925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer.
    Chi KN; Zoubeidi A; Gleave ME
    Expert Opin Investig Drugs; 2008 Dec; 17(12):1955-62. PubMed ID: 19012510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.
    Chi KN; Eisenhauer E; Fazli L; Jones EC; Goldenberg SL; Powers J; Tu D; Gleave ME
    J Natl Cancer Inst; 2005 Sep; 97(17):1287-96. PubMed ID: 16145049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen.
    Blumenstein B; Saad F; Hotte S; Chi KN; Eigl B; Gleave M; Jacobs C
    Cancer Med; 2013 Aug; 2(4):468-77. PubMed ID: 24156019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
    Sowery RD; Hadaschik BA; So AI; Zoubeidi A; Fazli L; Hurtado-Coll A; Gleave ME
    BJU Int; 2008 Aug; 102(3):389-97. PubMed ID: 18336596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer.
    Lamoureux F; Thomas C; Yin MJ; Kuruma H; Beraldi E; Fazli L; Zoubeidi A; Gleave ME
    Cancer Res; 2011 Sep; 71(17):5838-49. PubMed ID: 21737488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
    Saad F; Hotte S; North S; Eigl B; Chi K; Czaykowski P; Wood L; Pollak M; Berry S; Lattouf JB; Mukherjee SD; Gleave M; Winquist E;
    Clin Cancer Res; 2011 Sep; 17(17):5765-73. PubMed ID: 21788353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer.
    Miyake H; Hara I; Fujisawa M; Gleave ME
    Expert Opin Investig Drugs; 2006 May; 15(5):507-17. PubMed ID: 16634689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma.
    Xiu P; Dong XF; Li XP; Li J
    World J Gastroenterol; 2015 Jul; 21(27):8262-70. PubMed ID: 26217078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential use of custirsen to treat prostate cancer.
    Higano CS
    Onco Targets Ther; 2013; 6():785-97. PubMed ID: 23836992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer.
    Zhang X; Liu C; Li K; Wang K; Zhang Q; Cui Y
    Medicine (Baltimore); 2019 Feb; 98(6):e14254. PubMed ID: 30732140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.
    Chi KN; Hotte SJ; Yu EY; Tu D; Eigl BJ; Tannock I; Saad F; North S; Powers J; Gleave ME; Eisenhauer EA
    J Clin Oncol; 2010 Sep; 28(27):4247-54. PubMed ID: 20733135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.
    Chi KN; Higano CS; Blumenstein B; Ferrero JM; Reeves J; Feyerabend S; Gravis G; Merseburger AS; Stenzl A; Bergman AM; Mukherjee SD; Zalewski P; Saad F; Jacobs C; Gleave M; de Bono JS
    Lancet Oncol; 2017 Apr; 18(4):473-485. PubMed ID: 28283282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer.
    Chi KN; Siu LL; Hirte H; Hotte SJ; Knox J; Kollmansberger C; Gleave M; Guns E; Powers J; Walsh W; Tu D; Eisenhauer E
    Clin Cancer Res; 2008 Feb; 14(3):833-9. PubMed ID: 18245546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target.
    Muhammad LA; Saad F
    Expert Rev Anticancer Ther; 2015; 15(9):1049-61. PubMed ID: 26313417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clusterin as a therapeutic target for radiation sensitization in a lung cancer model.
    Cao C; Shinohara ET; Li H; Niermann KJ; Kim KW; Sekhar KR; Gleave M; Freeman M; Lu B
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1228-36. PubMed ID: 16253777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer.
    Zoubeidi A; Chi K; Gleave M
    Clin Cancer Res; 2010 Feb; 16(4):1088-93. PubMed ID: 20145158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer.
    Gleave ME; Miyake H; Zellweger T; Chi K; July L; Nelson C; Rennie P
    Urology; 2001 Aug; 58(2 Suppl 1):39-49. PubMed ID: 11502446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.